Johnson & Johnson and Viz.ai are pairing J&J’s neurovascular portfolio with Viz.ai’s FDA 510(k)-cleared Subdural Hemorrhage ...
RapidAI is showing no signs of slowing down after racking up a trio of FDA clearances since the start of the year. The latest of the agency nods was bestowed upon an artificial intelligence-powered ...
In the span of only about four years, Viz.ai has quickly racked up an impressive list of FDA permissions for its artificial intelligence algorithms designed to spot anomalies in emergency medical ...
Please provide your email address to receive an email when new articles are posted on . Rapid SDH demonstrated 92.4% sensitivity and 98.7% specificity in identifying subdural hematoma types. Median ...
In this multicenter, open-label, controlled, noninferiority trial, we randomly assigned symptomatic patients with chronic subdural hematoma in a 1:1 ratio to a 19-day tapering course of dexamethasone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results